Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v20-EN | Version v17-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2023-06-21 | 2023-06-08 |
| Drug Identification Number | 02513579 | 02513579 |
| Brand name | BIPAZEN | BIPAZEN |
| Common or Proper name | Desmopressin Acetate Injection | Desmopressin Acetate Injection |
| Company Name | KVR PHARMACEUTICALS INC. | KVR PHARMACEUTICALS INC. |
| Ingredients | DESMOPRESSIN ACETATE | DESMOPRESSIN ACETATE |
| Strength(s) | 4MCG | 4MCG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging size | Cartons of 10 ampoules | Cartons of 10 ampoules |
| ATC code | H01BA | H01BA |
| ATC description | POSTERIOR PITUITARY LOBE HORMONES | POSTERIOR PITUITARY LOBE HORMONES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-11-20 | 2022-11-20 |
| Actual start date | 2022-11-20 | 2022-11-20 |
| Estimated end date | 2023-06-21 | 2023-06-21 |
| Actual end date | 2023-06-20 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Back in stock. KVR has made the investment to produce three batches which have all been approved for release with the goal of carrying over a year of safety stock in the future. | A disruption of the manufacturing of an unreleased batch occurred, resulting in batch rejection. KVR has made the investment to produce three batches which have now all been approved for release with the goal of carrying over a year of safety stock in the future. |
| Health Canada comments |